NFKB1 and Hodgkins lymphoma: We suggest that in these cells, IL-6 secretion maybe inhibited through other pathways, independent of the proteasome.27 This may explain why bortezomib was not effective in inhibiting IL-6 secretion in L428 cells and failed as treatment for some HL patients.42, 43 Although, the idea of using bortezomib as an NF-κB inhibitor in the clinic has failed so far, nevertheless, better alternative NF-κB inhibitors have the potential to be successful in treating HL.